- Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020; 6: 92.
- Panarese I, Aquino G, Ronchi A, Longo F, Montella M, Cozzolino I, et al. Oral and oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route. Expert Rev Anticancer Ther. 2019; 19: 105-119.
- Kwan K, Han AY, Mukdad L, Barragan F, Selim O, Alhiyari Y, et al. Anticancer effects of thymoquinone in head and neck squamous cell carcinoma: a scoping review. Laryngoscope Investig Otolaryngol. 2023; 8: 876-885.
- Xing DT, Khor R, Gan H, Wada M, Ermongkonchai T, Ng SP. Recent research on combination of radiotherapy with targeted therapy or immunotherapy in head and neck squamous cell carcinoma: a review for radiation oncologists. Cancers (Basel). 2021; 13: 5716.
- Scarini JF, Lavareze L, de*Lima-Souza RA, Emerick C, Gonçalves MT, Figueiredo-Maciel T, et al. Head and neck squamous cell carcinoma: exploring frontiers of combinatorial approaches with tyrosine kinase inhibitors and immune checkpoint therapy. Crit Rev Oncol Hematol. 2022; 180: 103863.
- Kitamura N, Sento S, Yoshizawa Y, Sasabe E, Kudo Y, Yamamoto T. Current trends and future prospects of molecular targeted therapy in head and neck squamous cell carcinoma. Int J Mol Sci. 2020; 22: 240.
- Jackson JM, Wu EL, Brody L, Maxwell JH. Predictors of survival in veterans with head and neck cancer treated surgically. J Laparoendosc Adv Surg Tech A. 2023; 33: 566-569.
- Yao CMKL, Chang EI, Lai SY. Contemporary approach to locally advanced oral cavity squamous cell carcinoma. Curr Oncol Rep. 2019; 21: 99.
- Rajendiran S, Kpetemey M, Maji S, Gibbs LD, Dasgupta S, Mantsch R, et al. MIEN1 promotes oral cancer progression and implicates poor overall survival. Cancer Biol Ther. 2015; 16: 876-885.
- Liu CH, Chen HJ, Wang PC, Chen HS, Chang YL. Patterns of recurrence and second primary tumors in oral squamous cell carcinoma treated with surgery alone. Kaohsiung J Med Sci. 2013; 29:554-559.
- Yang C, Wang Z, Shi L, Liu W. Overview of oral cavity squamous cell carcinoma: risk factors, mechanisms, and diagnostics. Oral Oncol. 2021; 121:105451.
- Kushwaha PP, Gupta S, Singh AK, Kumar S. Emerging role of migration and invasion enhancer 1 (MIEN1) in cancer progression and metastasis. Front Oncol. 2019; 9: 868.
- Yin K, Ba Z, Li C, Xu C, Zhao G, Zhu S, et al. Overexpression of C35 in breast carcinomas is associated with tumor progression and lymph node metastasis. Biosci Trends. 2015; 9: 386-392.
- Dong X, Huang Y, Kong L, Li J, Kou J, Yin L, et al. C35 is overexpressed in colorectal cancer and is associated with tumor invasion and metastasis. Biosci Trends. 2015; 9: 117-121.
- Dasgupta S, Cushman I, Kpetemey M, Casey PJ, Vishwanatha JK. Prenylated c17orf37 induces filopodia formation to promote cell migration and metastasis. J Biol Chem. 2011; 286: 25935-25946.
- Dasgupta S, Wasson LM, Rauniyar N, Prokai L, Borejdo J, Vishwanatha JK. Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells. Oncogene. 2009; 28: 2860-2872.
- Liu QQ, Yin K, Zhu S, Zhang L, Wen PE, Li CL, et al. Inhibition of C35 gene expression by small interfering RNA induces apoptosis of breast cancer cells. Biosci Trends. 2010; 4: 254-259.
- Leung TH, Wong SC, Chan KK, Chan DW, Cheung AN, Ngan HY. The interaction between C35 and ΔNp73 promotes chemo-resistance in ovarian cancer cells. Br J Cancer. 2013; 109: 965-975.
- Katz E, Dubois-Marshall S, Sims AH, Faratian D, Li J, Smith ES, et al. A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk. Br J Cancer. 2010; 103:401-410.
- Evans EE, Henn AD, Jonason A, Paris MJ, Schiffhauer LM, Borrello MA, et al. C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer. Mol Cancer Ther. 2006; 5: 2919-2930.
- Almangush A, Mäkitie AA, Triantafyllou A, de Bree R, Strojan P, Rinaldo A, et al. Staging and grading of oral squamous cell carcinoma: an update. Oral Oncol. 2020; 107: 104799.
- Mitchell DA, Kanatas A, Murphy C, Chengot P, Smith AB, Ong TK. Margins and survival in oral cancer. Br J Oral Maxillofac Surg. 2018; 56: 820-829.
- Kalantari M, Alavi Samani A. A survey of oral and maxillofacial biopsies over a 23-year period in the southeast of Iran. J Dent Shiraz Univ Med Sci. 2022; 23: 298-306.
- Van Treuren T, Vishwanatha JK. CRISPR deletion of MIEN1 in breast cancer cells. PLoS One. 2018; 13:
- Zeng C, Guo J, Wu J, Che T, Huang X, Liu H, et al. HRD1 promotes non-small cell lung carcinoma metastasis by blocking autophagy-mediated MIEN1 degradation. J Biol Chem. 2023; 299: 104723.
- Cámara-Quílez M, Barreiro-Alonso A, Vizoso-Vázquez Á, Rodríguez-Belmonte E, Quindós-Varela M, Lamas-Maceiras M, et al. The HMGB1-2 ovarian cancer interactome: the role of HMGB proteins and their interacting partners MIEN1 and NOP53 in ovary cancer and drug-response. Cancers (Basel). 2020; 12: 2435.
- Zhao HB, Zhang XF, Wang HB, Zhang MZ. Migration and invasion enhancer 1 (MIEN1) is overexpressed in breast cancer and is a potential new therapeutic molecular target. Genet Mol Res. 2017; 16: gmr16019193.
- Agarwal D, Pardhe N, Bajpai M, Gupta S, Mathur N, Vanaki SS, et al. Characterization, localization and patterning of lymphatics and blood vessels in oral squamous cell carcinoma: a comparative study using D2‑40 and CD‑34 IHC marker. J Clin Diagn Res. 2014; 8: ZC86-ZC89.
- Liang F, Zhang H, Qiu Y, Xu Q, Jian K, Jiang L, et al. MiR-124-5p inhibits the progression of gastric cancer by targeting MIEN1. Technol Cancer Res Treat. 2020; 19:1533033820979199.
- Li D, Wei Y, Wang D, Gao H, Liu K. MicroRNA-26b suppresses the metastasis of non-small cell lung cancer by targeting MIEN1 via NF-κB/MMP-9/VEGF pathways. Biochem Biophys Res Commun. 2016; 472: 465-470.
- Rajendiran S, Parwani AV, Hare RJ, Dasgupta S, Roby RK, Vishwanatha JK. MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1. Mol Cancer. 2014; 13: 250.
|